Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HIMS Stock Forecast 2025-2026
$53.52
Current Price
$12.08B
Market Cap
Buy 5
Hold 7
Sell 2
Wall St Analyst Ratings
Distance to HIMS Price Targets
+58.8%
To High Target of $85.00
-20.6%
To Median Target of $42.50
-53.3%
To Low Target of $25.00
HIMS Price Momentum
-17.2%
1 Week Change
+100.4%
1 Month Change
+238.1%
1 Year Change
+121.3%
Year-to-Date Change
-26.7%
From 52W High of $72.98
+297.3%
From 52W Low of $13.47
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Hims (HIMS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on HIMS and similar high-potential opportunities.
Latest HIMS Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, HIMS has a neutral consensus with a median price target of $42.50 (ranging from $25.00 to $85.00). The overall analyst rating is Buy (6.9/10). Currently trading at $53.52, the median forecast implies a -20.6% downside. This outlook is supported by 5 Buy, 7 Hold, and 2 Sell ratings.
Conversely, the most conservative target is provided by Daniel Grosslight at Citigroup, suggesting a 53.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HIMS Analyst Ratings
5
Buy
7
Hold
2
Sell
HIMS Price Target Range
Low
$25.00
Average
$42.50
High
$85.00
Current: $53.52
Latest HIMS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HIMS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $61.00 |
| May 6, 2025 | Piper Sandler | Korinne Wolfmeyer | Neutral | Reiterates | $39.00 |
| May 6, 2025 | Citigroup | Daniel Grosslight | Sell | Maintains | $30.00 |
| Apr 29, 2025 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $40.00 |
| Apr 29, 2025 | B of A Securities | Allen Lutz | Underperform | Maintains | $26.00 |
| Apr 29, 2025 | TD Cowen | Jonna Kim | Hold | Downgrade | $30.00 |
| Apr 25, 2025 | Citigroup | Daniel Grosslight | Sell | Maintains | $25.00 |
| Apr 10, 2025 | Truist Securities | Jailendra Singh | Hold | Maintains | $33.00 |
| Mar 18, 2025 | B of A Securities | Allen Lutz | Underperform | Maintains | $22.00 |
| Mar 6, 2025 | Citigroup | Daniel Grosslight | Sell | Reiterates | $27.00 |
| Mar 6, 2025 | B of A Securities | Allen Lutz | Underperform | Reiterates | $21.00 |
| Feb 26, 2025 | Truist Securities | Jailendra Singh | Hold | Maintains | $39.00 |
| Feb 25, 2025 | Piper Sandler | Korinne Wolfmeyer | Neutral | Maintains | $35.00 |
| Feb 25, 2025 | Leerink Partners | Michael Cherny | Market Perform | Maintains | $40.00 |
| Feb 25, 2025 | Citigroup | Daniel Grosslight | Sell | Maintains | $27.00 |
| Feb 25, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $61.00 |
| Feb 20, 2025 | B of A Securities | Allen Lutz | Underperform | Maintains | $21.00 |
| Feb 19, 2025 | Canaccord Genuity | Maria Ripps | Buy | Maintains | $68.00 |
| Feb 18, 2025 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Downgrade | $60.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Sell | Downgrade | $25.00 |
Hims & Hers Health, Inc. (HIMS) Competitors
The following stocks are similar to Hims based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Hims & Hers Health, Inc. (HIMS) Financial Data
Hims & Hers Health, Inc. has a market capitalization of $12.08B with a P/E ratio of 79.4x. The company generates $1.78B in trailing twelve-month revenue with a 9.2% profit margin.
Revenue growth is +110.7% quarter-over-quarter, while maintaining an operating margin of +10.1% and return on equity of +36.8%.
Valuation Metrics
Market Cap
$12.08B
Enterprise Value
$12.72B
P/E Ratio
79.4x
PEG Ratio
117.3x
Price/Sales
6.8x
Growth & Margins
Revenue Growth (YoY)
+110.7%
Gross Margin
+73.5%
Operating Margin
+10.1%
Net Margin
+9.2%
EPS Growth
+344.7%
Financial Health
Cash/Price Ratio
+2.7%
Current Ratio
1.6x
Debt/Equity
11.5x
ROE
+36.8%
ROA
+10.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Hims & Hers Health, Inc. (HIMS) Business Model
About Hims & Hers Health, Inc.
What They Do
Provides telehealth services for personal care.
Business Model
The company operates a telehealth platform that enables users to consult licensed medical professionals online. It generates revenue by offering a range of personal care and wellness products, including prescription and over-the-counter medications, tailored to various health needs such as dermatology, sexual health, and mental wellness.
Additional Information
Hims & Hers is headquartered in San Francisco and is positioned in the expanding digital healthcare market, leveraging technology to enhance healthcare accessibility. The company benefits from the rising demand for telehealth services and the growth of e-commerce in healthcare solutions.
Company Information
Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
1,637
CEO
Mr. Andrew Dudum
Country
United States
IPO Year
2021
Website
www.hims.comHims & Hers Health, Inc. (HIMS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.
May 21, 2025
By Zacks Equity Research
Analyst Blog
AST Business Growth & Strategic Acquisitions Support STERIS Stock
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
May 21, 2025
By Zacks Equity Research
Analyst Blog
5 Single-Stock ETFs That Doubled in a Month
We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.
May 21, 2025
By Sweta Killa
ETF News and Commentary
Latest News
Quick Summary
Hims & Hers (HIMS) experienced significant volatility in 2025, with shares declining by 5.42%.
Why It Matters
Hims & Hers' volatile performance in 2025 signals potential risks and opportunities, affecting investor sentiment and stock price stability.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Hims and Hers, Inc. (NYSE: HIMS) shows bullish momentum with upward price action and rising support, indicating strong potential for growth despite volatility.
Why It Matters
Rising stock prices and bullish patterns indicate potential for profit, attracting investor interest and possibly driving up demand for Hims and Hers shares.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Hims & Hers reported Q1 2025 revenue growth of 111% YoY, driven by a subscription model. Management targets $6.5B in revenue by 2030, indicating potential undervaluation.
Why It Matters
Strong subscriber and revenue growth, alongside improved operating leverage and a clear path to $6.5B in revenue by 2030, signals potential for long-term profitability and stock appreciation.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Five single-stock ETFs have doubled in value over the past month, reflecting a significant recovery in the market.
Why It Matters
The surge in single-stock ETFs indicates strong investor confidence and potential market recovery, suggesting opportunities for high returns and influencing broader market trends.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Hims & Hers reports over 70% of new users choose AI-powered health plans, leading to increased recurring revenues and enhanced customer loyalty.
Why It Matters
Hims & Hers' AI-driven health plans boost user engagement and recurring revenues, indicating strong customer loyalty and growth potential, which could positively impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Hims & Hers stock surged nearly 16% on Tuesday, nearing its all-time high, as investors anticipate continued strong momentum in the coming years.
Why It Matters
Hims & Hers stock surge signals strong investor confidence, potentially indicating robust future performance and increased market interest, which could attract more capital and drive further price appreciation.
Source: Invezz
Market Sentiment:
Positive
Frequently Asked Questions About HIMS Stock
What is Hims & Hers Health, Inc.'s (HIMS) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Hims & Hers Health, Inc. (HIMS) has a median price target of $42.50. The highest price target is $85.00 and the lowest is $25.00.
Is HIMS stock a good investment in 2025?
According to current analyst ratings, HIMS has 5 Buy ratings, 7 Hold ratings, and 2 Sell ratings. The stock is currently trading at $53.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HIMS stock?
Wall Street analysts predict HIMS stock could reach $42.50 in the next 12 months. This represents a -20.6% decrease from the current price of $53.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Hims & Hers Health, Inc.'s business model?
The company operates a telehealth platform that enables users to consult licensed medical professionals online. It generates revenue by offering a range of personal care and wellness products, including prescription and over-the-counter medications, tailored to various health needs such as dermatology, sexual health, and mental wellness.
What is the highest forecasted price for HIMS Hims & Hers Health, Inc.?
The highest price target for HIMS is $85.00 from at , which represents a 58.8% increase from the current price of $53.52.
What is the lowest forecasted price for HIMS Hims & Hers Health, Inc.?
The lowest price target for HIMS is $25.00 from Daniel Grosslight at Citigroup, which represents a -53.3% decrease from the current price of $53.52.
What is the overall HIMS consensus from analysts for Hims & Hers Health, Inc.?
The overall analyst consensus for HIMS is neutral. Out of 20 Wall Street analysts, 5 rate it as Buy, 7 as Hold, and 2 as Sell, with a median price target of $42.50.
How accurate are HIMS stock price projections?
Stock price projections, including those for Hims & Hers Health, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 3:18 AM UTC